GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » Total Liabilities

SQI Diagnostics (FRA:XSQ) Total Liabilities : €12.63 Mil (As of Mar. 2023)


View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics Total Liabilities?

SQI Diagnostics's Total Liabilities for the quarter that ended in Mar. 2023 was €12.63 Mil.

SQI Diagnostics's quarterly Total Liabilities declined from Sep. 2022 (€14.48 Mil) to Dec. 2022 (€13.54 Mil) and declined from Dec. 2022 (€13.54 Mil) to Mar. 2023 (€12.63 Mil).

SQI Diagnostics's annual Total Liabilities increased from Sep. 2020 (€4.07 Mil) to Sep. 2021 (€5.06 Mil) and increased from Sep. 2021 (€5.06 Mil) to Sep. 2022 (€14.48 Mil).


SQI Diagnostics Total Liabilities Historical Data

The historical data trend for SQI Diagnostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics Total Liabilities Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.58 3.25 4.07 5.06 14.48

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.56 14.14 14.48 13.54 12.63

SQI Diagnostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SQI Diagnostics's Total Liabilities for the fiscal year that ended in Sep. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.105+(6.378+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=14.48

Total Liabilities=Total Assets (A: Sep. 2022 )-Total Equity (A: Sep. 2022 )
=7.053--7.429
=14.48

SQI Diagnostics's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.625+(5.005+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=12.63

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=2.679--9.951
=12.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SQI Diagnostics Total Liabilities Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (FRA:XSQ) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines